RxDoctor Payments Data

Luis Vazquez, MD

Ophthalmology · Miami, FLNPI 1083989719

Payments from drug & device makers

$7,098in general payments, 2019–2025

Across 27 payments — averaging $262.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • NEW World Medical,inc.$5K
  • W. L. Gore & Associates, Inc.$1K
  • AbbVie$372
  • Aerie Pharmaceuticals, Inc.$328
  • Alcon$284
  • Bausch & Lomb Americas Inc.$204
  • plus $180 from 3 others

What the payments were for

  • Consulting fees$4,44063%
  • Speaking & faculty fees$1,00014%
  • Food & beverage$1,65823%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,098 in reported general payments places this provider in the 75th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$148,835
Medicare patients
545
Services billed
1,877

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate314$111,720
Methazolamide428$78,948
LumiganBimatoprost186$67,086
Restasis MultidoseCyclosporine78$55,199
RocklatanNetarsudil Mesylat/Latanoprost141$52,934
VyzultaLatanoprostene Bunod136$45,463
RestasisCyclosporine67$44,396
Prednisolone Acetate543$28,648
CombiganBrimonidine Tartrate/Timolol69$24,278
Latanoprost3,812$23,112
Alphagan PBrimonidine Tartrate45$19,613
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat1,568$17,513
Travoprost142$16,385
Timolol Maleate1,303$13,789
IlevroNepafenac32$11,924

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis Multidose, Restasis, Combigan, Alphagan P$372$210,573445 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$328$164,654455 claims
Bausch & Lomb Americas Inc.Vyzulta$204$45,463136 claims
AlconAzopt, Simbrinza$284$14,88553 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →